Altered iron metabolism, inflammation, transferrin receptors, and ferritin expression in non-small-cell lung cancer

Medical Oncology

Volumn 27, Issue 2, 2010, Pages 268-277

  Kukulj, Suzana ^a   Jaganjac, Morana ^b   Boranic, Milivoj ^b   Krizanac, Simun ^c   Santic, Zarko ^d   Poljak Blazi, Marija ^b  

^a University Hospital for Lung Diseases Jordanovac   (Croatia)

^b RUDER BO KOVI INSTITUTE   (Croatia)

^c University of Zagreb   (Croatia)

^d UNIVERSITY OF MOSTAR   (Bosnia and Herzegovina)

Author keywords

Body iron stores; Ferritin; ICF; Inflammation; Non small cell lung carcinoma; Transferrin receptors

Indexed keywords

ALPHA 1 GLOBULIN; ALPHA 2 GLOBULIN; ALPHA GLOBULIN; CD71 ANTIGEN; FERRITIN; IRON; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CORRELATION ANALYSIS; CROATIA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FERRITIN BLOOD LEVEL; HEMATOCRIT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; IRON DEFICIENCY; IRON METABOLISM; IRON OVERLOAD; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-GLOBULINS; ANTIGENS, CD; BLOOD SEDIMENTATION; CARCINOMA, NON-SMALL-CELL LUNG; FERRITINS; HUMANS; INFLAMMATION; IRON METABOLISM DISORDERS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OXIDATIVE STRESS; RECEPTORS, TRANSFERRIN; SURVIVAL RATE;

EID: 77956928536     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9203-2     Document Type: Article

References (41)

1. Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. N Engl J Med. 1988;319(16):1047-52.
2. Weinberg ED. Association of iron with respiratory tract neoplasia. J Trace Elem Exp Med. 1993;6:117-23.
3. Stevens RG, Graubard BI, Micozzi MS, Neriishi K, Blumberg BS. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer. 1994;56(3):364-9.doi:10.1002/ijc.2910560312.
4. Knekt P, et al. Body iron stores and risk of cancer. Int J Cancer. 1994;56(3):379-82. doi:10.1002/ijc.2910560315.
5. Weinberg ED. The role of iron in cancer. Eur J Cancer Prev. 1996;5(1):19-36. doi:10.1097/000199608469-199609001-00004.
6. Lapenna D, et al. Cigarette smoke, ferritin, and lipid peroxidation. Am J Respir Crit Care Med. 1995;151(2Pt 1):431-5.
7. Richardson DR, Ponka P. The molecular mechanisms of themetabolism and transport of iron in normal and neoplastic cells.Biochim Biophys Acta. 1997;1331(1):1-40.
8. Haile DJ. Regulation of genes of iron metabolism by the ironresponse proteins. Am J Med Sci. 1993;318(4):230-40. doi:10.1097/00000441-199910000- 00003.
9. Faulk WP, Hsi BL, Stevens PJ. Transferrin and transferring receptors in carcinoma of the breast. Lancet. 1980;2(8191):390-2.
10. Habeshaw JA, Lister TA, Stansfeld AG, Greaves MF. Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. Lancet. 1983;1(8323):498-501. doi:10.1016/S0140-6736(83) 92191-8.
11. Wrba F, Ritzinger E, Reiner A, Holzner JH. Transferrin receptor (TrfR) expression in breast carcinoma and its possible relationship to prognosis. An immunohistochemical study. Virchows Arch A Pathol Anat Histopathol. 1986;410(1):69-73. doi: 10.1007/BF00710908.
12. Octave JN, Schneider YJ, Hoffmann P, Trouet A, Crichton RR. Transferrin protein and iron uptake by cultured rat fibroblasts. FEBS Lett. 1979;108(1):127-30. doi:10.1016/0014-5793(79) 81193-X.
13. Larrick JW, Cresswell P. Transferrin receptors on human B and T lymphoblastoid cell lines. Biochim Biophys Acta. 1979;583(4): 483-90.
14. Larson SM, et al. Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor. J Natl Cancer Inst. 1980;64(1):41-53.
15. Delia D, et al. Modulation of T leukaemic cell phenotype with phorbol ester. Int J Cancer. 1982;29(1):23-31. doi:10.1002/ijc.29 10290106.
16. Ponka P, Beaumont C, Richardson DR. Function and regulation of transferrin and ferritin. Semin Hematol. 1998;35(1):35-54.
17. Yamanishi H, Iyama S, Yamaguchi Y, Kanakura Y, Iwatani Y. Relation between iron content of serum ferritin and clinical status factors extracted by factor analysis in patients with hyperferritinemia. Clin Biochem. 2002;35(7):523-9. doi:10.1016/S0009-9120(02)00380-6. (Pubitemid 35462127)
18. Travis WD, Colby TV, Corrin B, et al. Histological typing of lung and pleural tumours. World Health Organization International Histological Classification of Tumors, XIII. 3rd ed. Berlin/ Heidelberg: Springer-Verlag; 1999.
19. Sobin LH, Wittekind CL. TNM classification of malignant tumors. 6th ed. New York: John Wiley & Sons, Inc.; 2002.
20. Whitney JF, Clark JM, Griffin TW, Gautam S, Leslie KO. Transferrin receptor expression in nonsmall cell lung cancer. Histopathologic and clinical correlates. Cancer. 1995;76(1):20-5. doi:10.1002/1097-0142(19950701)76:1<20:: AID-CNCR2820760104>3.0.CO;2-3.
21. Yang HB, et al. Adenoma-carcinoma sequence: a reappraisal with immunohistochemical expression of ferritin. J Surg Oncol. 1995; 60(1):35-40. doi:10.1002/jso.2930600108.
22. Nakano M, et al. Oxidative DNA damage (8-hydroxydeoxyguanosine) and body iron status: a study on 2507 healthy people. Free Radic Biol Med. 2003;35(7):826-32. doi:10.1016/S0891- 5849(03)00432-5.
23. Zaniboni A, et al. Phase II study oftaxol combined with ifosfamide and carboplatin in the treatment of stage IIIb-IV non-smallcell lung cancer. Am J Clin Oncol. 2003;26(1):84-8. doi:10.1097/00000421-200302000-00016. (Pubitemid 36205902)
24. Fujimoto T, et al. Completely resected N1 non-small-cell lung cancer: factors affecting recurrence and long-term survival. J Thorac Cardivasc Surg. 2006;132(3):499-506. doi:10.1016/j.jtcvs. 2006.04.019.
25. Yovino S, Kwok Y, Krasna M, Bangalore M, Suntharalingam M. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone. Int J Radiat Oncol Biol Phys. 2005;62(5):1438-43. doi:10.1016/j.ijrobp.2004.12.038. (Pubitemid 40982067)
26. Berardi R, et al. Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancers. Lung Cancer. 2005;49(3):371-6. doi:10.1016/ j.lungcan.2005.04.011.
27. Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev. 2002;16(2):87-96. doi:10.1054/blre.2002.0193. (Pubitemid 34742225)
28. Prutki M, et al. Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer. Cancer Lett. 2006; 238(2):188-96. doi:10.1016/j.canlet.2005.07.001. (Pubitemid 43867908)
29. Hyman GA, Harvey JE. The pathogenesis of anaemia in patients with carcinoma. Am J Med. 1955;19(3):350-6. doi:10.1016/0002-9343(55)90123-6.
30. Li R, Luo C, Mines M, Zhang J, Fan GH. CV hemocine CXCL12 induces binding of ferritin heavy chain to the chemokine receptor CXCR4, alters CXCR4 signaling, and induces phosphorylation and translocation of ferritin heavy chain. J Biol Chem. 2006;281(49):37616-27. doi:10.1074/jbc.M607266200. (Pubitemid 46042064)
31. Harada T, Baba M, Torii I, Morikawa S. Ferritin selectively suppresses delayed-type hypersensitivity responses at induction or effector phase. Cell Immunol. 1987;109(1):75-88. doi:10.1016/0008-8749(87)90293-0. (Pubitemid 17155710)
32. Moroz C, et al. Treatment of human bone marrow with recombinant placenta immunomodulator ferritin results in myelopoiesis a T-cell suppression through modulation of the cytokine-chemokine networks. Exp Hematol. 2006;34(2):159-66. doi:10.1016/j.exphem.2005.10.006. (Pubitemid 43184321)
33. Dallegri F, Patrone F, Frumento G, Sacchetti C. Antibodydependent killing of tumor cells by polymorphonuclear leukocytes. Involvement of oxidative and nonoxidative mechanisms. J Natl Cancer Inst. 1984;73(2):331-9.
34. Dallegri F, Frumento G, Ballestrero A, Goretti R, Patrone F. Relationship between antibody-dependent tumour cell lysis and primary granule exocytosis by human neutrophils. Clin Exp Immunol. 1987;70(2):479-83.
35. Valerius T, et al. Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood. 1993;82(3):931-9.
36. Reali E, et al. Interferon-γ enhances monoclonal antibody 17-1Adependent neutrophil cytotoxicity toward colorectal carcinoma cell line SW11-16. Clin Immunol Immunopathol. 1994;71(1): 105-12. doi:10.1006/clin.1994. 1058.
37. Katano M, Torisu M. Neutrophil-mediated tumor cell destruction in cancer ascites. Cancer. 1982;50(1):62-8. doi:10.1002/1097-0142(19820701)50:1\62::AID- CNCR2820500113[3.0.CO;2-0. (Pubitemid 12084854)
38. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539-45. doi:10.1016/S0140-6736(00)04046-0. (Pubitemid 32173595)
39. O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer. 2001;85(4):473-83. doi:10.1054/bjoc.2001. 1943. (Pubitemid 32808267)
40. Prutki M, Poljak-Blazi M, Mihaljevic B, Orescanin V, Zarkovic N. Uptake of anti-anemic substance ferric-sorbitol-citrate by normal and malignant cells and its effects on expression of transferrin receptor 1 and ferritin. Cancer Biother Radiopharm. 2006;21(6):636-44. doi:10.1089/cbr.2006.21.636. (Pubitemid 46175700)
41. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. 2nd ed. Oxford: Clarendon Press; 1989. 466.